Compile Data Set for Download or QSAR
maximum 50k data
Found 14 Enz. Inhib. hit(s) with all data for entry = 6946
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160935(US10167299, Maraviroc | US9107954, maraviroc)
Affinity DataKi:  0.240nMAssay Description:Afterwards, the pharmacological profile of bivalent ligand 1 at the chemokine receptor CCR5 was characterized similarly. The competitive radioligand ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM60212((4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-bis(o...)
Affinity DataKi:  0.700nMAssay Description:A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule w...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160933(US9107954, 2)
Affinity DataKi:  9.20nMAssay Description:A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule w...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160934(US9107954, 4)
Affinity DataKi:  15.3nMAssay Description:Afterwards, the pharmacological profile of bivalent ligand 1 at the chemokine receptor CCR5 was characterized similarly. The competitive radioligand ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataKi:  51.8nMAssay Description:A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule w...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160932(US9107954, 3)
Affinity DataKi:  151nMAssay Description:Afterwards, the pharmacological profile of bivalent ligand 1 at the chemokine receptor CCR5 was characterized similarly. The competitive radioligand ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataKi:  239nMAssay Description:Afterwards, the pharmacological profile of bivalent ligand 1 at the chemokine receptor CCR5 was characterized similarly. The competitive radioligand ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160935(US10167299, Maraviroc | US9107954, maraviroc)
Affinity DataIC50:  2.20nMAssay Description:Then the Ca2+ functional activity of bivalent ligand 1 was evaluated in the Gqi5 transfected CCR5-MOLT-4 cells as described in the literature.3 As ex...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM60212((4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-bis(o...)
Affinity DataIC50:  8.90nMAssay Description:As Ca2+ flux is associated with the activation of the MOR, the functional activity of bivalent ligand 1, monovalent ligand 2, and naltrexone was then...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160934(US9107954, 4)
Affinity DataIC50:  14.2nMAssay Description:Then the Ca2+ functional activity of bivalent ligand 1 was evaluated in the Gqi5 transfected CCR5-MOLT-4 cells as described in the literature.3 As ex...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160933(US9107954, 2)
Affinity DataIC50:  37.8nMAssay Description:As Ca2+ flux is associated with the activation of the MOR, the functional activity of bivalent ligand 1, monovalent ligand 2, and naltrexone was then...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataIC50:  40nMAssay Description:As Ca2+ flux is associated with the activation of the MOR, the functional activity of bivalent ligand 1, monovalent ligand 2, and naltrexone was then...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataIC50:  126nMAssay Description:Then the Ca2+ functional activity of bivalent ligand 1 was evaluated in the Gqi5 transfected CCR5-MOLT-4 cells as described in the literature.3 As ex...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160932(US9107954, 3)
Affinity DataIC50:  622nMAssay Description:Then the Ca2+ functional activity of bivalent ligand 1 was evaluated in the Gqi5 transfected CCR5-MOLT-4 cells as described in the literature.3 As ex...More data for this Ligand-Target Pair
In DepthDetails US Patent